Resumen de acción PRTCL PureTech Health plc, se dedica al desarrollo y comercialización de soluciones biotecnológicas y farmacéuticas en Estados Unidos. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de PureTech Health plc Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del PureTech Health Precios históricos de las acciones Precio actual de la acción UK£1.56 Máximo en las últimas 52 semanas UK£2.39 Mínimo de 52 semanas UK£1.39 Beta 0.95 Cambio en 1 mes -8.47% Variación en 3 meses -0.64% Cambio de 1 año -20.53% Variación en 3 años -46.34% Variación en 5 años -50.13% Variación desde la OPV 15.80%
Noticias y actualizaciones recientes PureTech Health plc(LSE:PRTC) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)
PureTech Health plc Presents Data for LYT-200 (anti-Galectin-9 Monoclonal Antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting Dec 10
PureTech Health plc Appoints Sandi Peterson to Its Board of Directors Nov 20
PureTech Health plc Appoints Lauren White as Chief Financial Officer Nov 06
Puretech Health plc Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis and Use of A Bayesian Stat Analysis for Lyt-100 (Deupirfenidone) At Chest 2024 Annual Meeting Oct 09
PureTech Health plc Announces KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults Sep 27 Ver más actualizaciones PureTech Health plc(LSE:PRTC) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)
PureTech Health plc Presents Data for LYT-200 (anti-Galectin-9 Monoclonal Antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting Dec 10
PureTech Health plc Appoints Sandi Peterson to Its Board of Directors Nov 20
PureTech Health plc Appoints Lauren White as Chief Financial Officer Nov 06
Puretech Health plc Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis and Use of A Bayesian Stat Analysis for Lyt-100 (Deupirfenidone) At Chest 2024 Annual Meeting Oct 09
PureTech Health plc Announces KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults Sep 27
Puretech Health plc Appoints Michele Holcomb as Independent Non-Executive Director, Effective September 23, 2024 Aug 22
PureTech Health plc to Report First Half, 2024 Results on Aug 28, 2024 Aug 21
PureTech Health plc Appoints David Wheadon to Its Board of Directors Aug 14
PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors Jun 20 PureTech Health plc (LSE:PRTC) announces an Equity Buyback for 33,500,000 shares, representing 12.37% for $100 million. May 21
Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments May 08
PureTech Health plc, Annual General Meeting, Jun 13, 2024 Apr 27
Full year 2023 earnings released: US$0.24 loss per share (vs US$0.18 loss in FY 2022) Apr 25
PureTech Health plc to Report Fiscal Year 2023 Results on Apr 25, 2024 Apr 19
PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis Apr 16
PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers Apr 12 PureTech Health plc Announces Chief Executive Officer Changes
New major risk - Revenue and earnings growth Feb 06
Puretech Health plc Presents Data from Phase 1 Trial of Lyt-200 Targeting Galectin-9 in Solid Tumors At the Esmo Immuno-Oncology Congress 2023 Dec 07
Puretech Health plc Announces Topline Results from Its Phase 2A, Randomized, Placebo-Controlled, Proof-Of-Concept Trial of LYT-300 Nov 14
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults At Chest Annual Meeting Oct 12
Puretech Announces the Appointment of Robert Lyne as Chief Portfolio Officer Sep 27
First half 2023 earnings released: US$0.09 loss per share (vs US$0.098 loss in 1H 2022) Aug 30
PureTech Health plc to Report First Half, 2023 Results on Aug 29, 2023 Aug 22
PureTech Health plc Receives Up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-Associated Tremor/Ataxia Syndrome Aug 02
Puretech Health plc Initiates Phase 2A Clinical Trial of Lyt-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders Jun 22
Full year 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in FY 2021) Apr 30
PureTech Health plc to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression Feb 15
PureTech Health plc Announces Executive Changes Dec 22
PureTech Health plc Announces Topline Results from the Completed, Multi-Part Phase 1 Trial of LYT-300 Dec 21
PureTech Health plc Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology Annual Meeting Dec 13
PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform Dec 01
Nektar Therapeutics (NasdaqGS:NKTR) cancelled the acquisition of PureTech Health plc (LSE:PRTC). Oct 11
Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC). Oct 08
PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022 Sep 07
PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022 Sep 06
First half 2022 earnings released: US$0.098 loss per share (vs US$0.26 loss in 1H 2021) Aug 26
PureTech Health plc to Report First Half, 2022 Results on Aug 25, 2022 Aug 04
PureTech Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan Aug 02
PureTech Health plc Announces New Akili Data in Lupus Jul 15
Puretech Health plc Announces the Initiation of A Clinical Study of LYT-100 Jul 01 PureTech Health plc(LSE:PRTC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)
PureTech Health plc Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications Jun 14
PureTech Health plc and Akili Interactive Labs, Inc. Appoints Matt Franklin as President and Chief Operating Officer, Effective June 21, 2022 Jun 07
PureTech Health plc Presents Additional Phase 1 Data for LYT-100 May 17
Full year 2021 earnings released: US$0.21 loss per share (vs US$0.021 profit in FY 2020) Apr 27
PureTech Health plc, Annual General Meeting, Jun 15, 2022 Apr 26
Puretech Founded Entity Vedanta Biosciences Publishes Phase 1A/1B Results for Lead Program Ve303 in Cell Host & Microbe and Highlights Plann Presentations of Phase 2 Ve303 Results Apr 14
PureTech Health plc Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine Apr 12
PureTech Health plc to Report Fiscal Year 2021 Results on Apr 26, 2022 Apr 07
President recently bought UK£51k worth of stock Feb 05
PureTech Health plc Announces LYT-100 Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone Jan 06
President recently bought UK£73k worth of stock Dec 23
PureTech Health plc Reports on the Key Progress Made Across its Wholly Owned Programs 1 and Founded Entities 2 in 2021 Dec 17
PureTech Health plc's Lymphatic Platform Candidate Human Study Dec 09
PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance Sep 21
Puretech Health plc Presents LYT-100 Ph1 PK & Tolerability At ERS Aug 25
First half 2021 earnings released: US$0.26 loss per share (vs US$0.43 profit in 1H 2020) Aug 25
President recently bought UK£83k worth of stock Jul 24
PureTech Health plc Announces Additional Results from Phase 1 Study in Healthy Volunteers of VE202 Jul 01
President recently bought UK£69k worth of stock Jun 25
PureTech Health plc (LSE:PRTC) acquired the remaining 22% stake in Alivio Therapeutics. Jun 17
Puretech’s Gelesis Presents Plenity Data at American Association of Clinical Endocrinology 2021 May 28
COO, Secretary & Executive Director has left the company May 19
Full year 2020 earnings released: EPS US$0.02 (vs US$1.49 in FY 2019) Apr 17
PureTech Health plc Announces Executive Changes Mar 18
PureTech Health plc to Report Fiscal Year 2020 Final Results on Apr 15, 2021 Mar 15
PureTech Announces Publication of Glyph™ Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release Feb 26
New 90-day high: UK£4.10 Feb 20
PureTech Names Bharatt Chowrira to Board of Directors Feb 08
PureTech Health plc Appoints Bharatt Chowrira to its Board of Directors Jan 29
PureTech Health plc Announces Management Appointments Jan 15
PureTech Announces the Appointment of George Farmer as Chief Financial Officer Jan 05
New 90-day high: UK£3.69 Dec 23
Investor sentiment improved over the past week Dec 18
PureTech Health plc Starts LYT-200 Clinical Trial in Solid Tumors Dec 13
PureTech Health plc Initiates Phase 2A Trial of LYT-100 (Deupirfenidone) in Lymphedema Dec 12
New 90-day high: UK£3.06 Dec 04
PureTech Initiates Phase 2 Trial of LYT-100 (Deupirfenidone) in Long COVID Respiratory Complications and Related Sequelae Dec 04
PureTech Health plc Announces the Completion of A Phase 1 Multiple Ascending Dose and Food Effect Study for LYT-100 Nov 18
PureTech Health plc Appoints Kiran Mazumdar-Shaw to Its Board of Directors Oct 01
PureTech Health plc to Report First Half, 2020 Results on Aug 27, 2020 Aug 07 Rentabilidad de los accionistas PRTCL GB Biotechs Mercado GB 7D -0.4% -0.2% 0.5% 1Y -20.5% -25.8% 2.7%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: PRTCL superó a la industria UK Biotechs, que obtuvo un rendimiento del -25.8% el año pasado.
Rentabilidad vs. Mercado: PRTCL obtuvo unos resultados inferiores a los del mercado UK, que fueron del 2.7% el año pasado.
Volatilidad de los precios Is PRTCL's price volatile compared to industry and market? PRTCL volatility PRTCL Average Weekly Movement 6.2% Biotechs Industry Average Movement 7.0% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Precio estable de las acciones: PRTCL no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de PRTCL (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa PureTech Health plc, se dedica al desarrollo y comercialización de soluciones biotecnológicas y farmacéuticas en Estados Unidos. La empresa está desarrollando LYT-100, en fase 2, para tratar la fibrosis pulmonar idiopática (FPI); y LYT-200, un anticuerpo monoclonal IgG4, actualmente en fase 1/2, dirigido a la galectina-9 para tratar tumores sólidos y neoplasias hematológicas. También desarrolla SPT-300, un fármaco oral de alopregnanolona para el tratamiento de la depresión ansiosa; SPT-320, un nuevo profármaco de agomelatina para el tratamiento del trastorno de ansiedad generalizada; y SPT-348, un profármaco de un neuroplastogeno no alucinógeno para el tratamiento del estado de ánimo y otros trastornos neuropsiquiátricos.
Mostrar más Resumen de fundamentos de PureTech Health plc ¿Cómo se comparan los beneficios e ingresos de PureTech Health con su capitalización de mercado? Estadísticas fundamentales de PRTCL Capitalización bursátil UK£370.62m Beneficios(TTM ) -UK£65.83m Ingresos (TTM ) UK£373.56k
992.1x Ratio precio-ventas (PS)
-5.6x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de PRTCL Ingresos US$468.00k Coste de los ingresos US$82.02m Beneficio bruto -US$81.55m Otros gastos US$917.00k Beneficios -US$82.47m
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.34 Margen bruto -17,425.00% Margen de beneficio neto -17,620.94% Ratio deuda/patrimonio 40.7%
¿Cómo se ha desempeñado PRTCL a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/27 05:15 Precio de las acciones al final del día 2024/12/24 00:00 Beneficios 2024/06/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas PureTech Health plc está cubierta por 8 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Peter Welford Jefferies LLC Thomas Smith Leerink Partners LLC Faisal Khurshid Leerink Partners LLC
Mostrar 5 más analistas 
